Thank you for standing by. My name is Cass, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ceribell Third Quarter 2024 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. I would now like to turn the call over to Brian Johnston from Gilmartin Group. Please go ahead. Good afternoon, and thank you all for participating in today's call. Joining me from Ceribell are Jane Chao, Co-founder and Chief Executive Officer, and Scott Blumberg, Chief Financial Officer. Earlier today, Ceribell issued a press release announcing financial results for the quarter ending September 30th, 2024. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws and that these are being made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions, future events, results, or performance are forward-looking statements. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the risk factors section of our public filings with the Securities and Exchange Commission, including the final prospectus filed with the SEC pursuant to Rule 424(b)(4) on October 11th, 2024, in connection with our initial public offering. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, November 12th, 2024. Ceribell disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. With that, I will now turn the call over to Jane. Thank you, Brian. Good afternoon, and thank you all for joining us today on our first earnings call as a public company. We are very excited to be here and to provide details on our strong third-quarter performance. We will also briefly review our growth strategy and cover our key focus areas for the quarters and years ahead. Before doing so, I'd first like to take this opportunity to thank all our shareholders who have supported Ceribell since its inception. In particular, I'd like to thank those who participated in our recently completed initial public offering, which raised approximately $188 million in net proceeds. I would also like to thank the entire Ceribell team, our board of directors, and most of all, our customers who are saving lives every day. With your support and dedication, the future for Ceribell and the patients we serve has never been brighter. Turning now to a brief overview of our results, I'm pleased to report that the revenue for the third quarter of 2024 was $17.2 million. This represents 48% growth year over year. Meanwhile, the gross margin for the third quarter was 87%. As we will detail later, our performance was driven by continued progress in acquiring new customers and improving adoption by our established account base. For the rest of this call, I will first provide a brief introduction to Ceribell technology, the unmet need we're addressing. I'll then provide further details on our commercial performance and the vision for the future. Scott will provide additional details in our quarterly financial results and our full year 2024 revenue guidance. At the highest level, we're focused on commercialization of the Ceribell system, our novel point-of-care EEG platform, specifically designed to address the unmet needs in the patient in the acute care setting. Our platform solution, which includes our highly portable, easy-to-use hardware and the AI-powered algorithm, enables rapid diagnosis and continuous monitoring of patients at risk of serious neurological conditions. The Ceribell system is commercially available in the United States, where our initial focus is on seizure detection and management in the ICU and ED. We believe this represents an over $2 billion addressable market opportunity in the U.S. alone. In the acute care settings, status epilepticus or seizure lasting longer than five minutes is a medical emergency. If not promptly treated, the condition can lead to mortality or severe and permanent brain injury. Seizures leading to status epilepticus can be triggered by a variety of common conditions, including brain tumor, traumatic brain injury, stroke, cardiac arrest, and sepsis, among others. We believe that there are roughly three million patients in the U.S. who arrive in the acute care setting and are at risk for seizures. In the ICU, up to 92% of these seizures may be non-convulsive. Patients do not show visible symptoms, making diagnosis very challenging. EEG is the only tool to definitively confirm a seizure diagnosis. Historically, the only tool that clinicians have had to diagnose seizure has been the conventional EEG, which was optimized for outpatient clinics, not for the acute care setting. Conventional EEG systems have several inherent limitations, making timely diagnosis and continuous monitoring difficult and, in some cases, impossible. The Ceribell system changes this, enabling rapid EEG deployment and continuous monitoring for seizure activity. After less than an hour of training, nurses and non-specialized healthcare professionals can easily set up the Ceribell system in as little as five minutes. The Ceribell system can capture EEG waveforms with the signal quality clinically equivalent to conventional EEG and transmit the EEG signals to our EEG portal for neurologists to remotely review. Clarity, our AI algorithm, continuously monitors the EEG, providing bedside alerts for status epilepticus, seizure trends, and other actionable insights to bedsides and neurologists. Through Clarity, clinicians can have higher confidence in treat promptly or not treat. With continuous monitoring, they can reduce the time patients spend in seizures. They also benefit from real-time feedback on patients' response to medication. Importantly, we believe the Ceribell system can also improve the hospital and payer economics by enabling multiple pathways for appropriate reimbursement and cost saving. We have demonstrated across several studies that the Ceribell system can decrease the average hospital length of stay, reduce over-administration of anti-seizure medication, and reduce unnecessary patient transfer. In addition, confirmed diagnosis of seizure may allow hospitals to receive appropriate reimbursement coding for more complex and costly management of patients with multiple comorbidities, and finally, Ceribell is the only EEG system that qualifies for a New Technology Add-on Payment from CMS, which provides hospitals additional Medicare reimbursement of up to $913.90 for eligible patients. These clinical and economic benefits, as well as the technical performance of the Ceribell system, have been validated across 20 peer-reviewed publications and 65 abstracts. Now, I shift to an overview of our commercial approach and how it has translated to strong third-quarter performance. For perspective, we estimated that there are 5,800 acute care facilities in the U.S. that stand to benefit from our offering. To fully penetrate this significant market, our commercial organization comprises two core components. Our territory managers drive account acquisition and onboarding, and our clinical account managers drive utilization and hospital onboarding. Through joint efforts of these sales functions, Ceribell has been able to continually expand its active account base while generally increasing utilization within our existing account base. Our active account base now sits at 504 accounts, an increase of 25 during the third quarter. Within this account base, we have continually increased the usage over the past three years, roughly doubling usage per account during this time frame. Just yesterday, we were also pleased to announce our receipt of our authority to operate, or ATO, from the Department of Veterans Affairs. This ATO represents a significant milestone in achieving authorization within the framework of the federal government cloud computing security requirements. Practically, it allows the nearly 200 VA hospitals in the U.S. to fully deploy Ceribell's point-of-care EEG technology, including Clarity and our other cloud-based services. We're humbled to be one of the very few medical device companies to receive an ATO from the VA and believe this will enable us to offer many advantages of the Clarity and the Ceribell system to the veterans who are at an elevated risk level of being diagnosed with a seizure disorder due to the conditions such as traumatic brain injury and post-traumatic stress disorders. Looking ahead, we are continuing to invest in the expansion of both sides of our commercial organizations as we look to capture the significant untapped opportunities within our market. Beyond investing in our commercial organization, we also intend to drive further awareness regarding the importance of acute care EEG monitoring and the unique features and capabilities of our platform solution. To accomplish this, we are directly engaging with clinicians, investing in marketing initiatives, and, importantly, generating further clinical and economic data. This data stands to further validate the benefits provided by the Ceribell system and the early detection and treatment of status epilepticus generally. In July, we were pleased to see the results from a new retrospective sub-analysis of a multicenter clinical study demonstrating positive patient outcomes following using the Ceribell system compared to the conventional EEG published in the Neurocritical Care, the journal of the Neurocritical Care Society. The study showed that the use of the Ceribell system is associated with a significant four-day reduction in ICU length of stay on average. It also showed that patients using Ceribell EEG were 33% less likely to leave the hospital with significant functional disability. These findings, along with four other abstracts, were represented at the 2024 Neurocritical Care Society annual meeting in October. We see this positive data as representative of our commitment to being at the forefront of clinical innovation and data generation in our space. As we look ahead, we also see several clear use cases for our platform beyond our current indication. In the near term, we are seeking to expand the age coverage of patients eligible for our Clarity algorithm. Currently, our hardware is approved for all ages, but Clarity's seizure detection algorithm is only approved for patients 18 and up. Over the medium term, we expect to move beyond seizure detection. Brain function often remains a black box, even in the best ICUs. Though EEG has historically been limited to the identification of seizures, EEGs have been scientifically demonstrated to aid in detection of a wide variety of other neurological conditions. We intend to leverage our proprietary platform and our AI capabilities to develop algorithms for some of these conditions, including delirium and stroke. I look forward to providing additional updates on these exciting opportunities on our future calls. To summarize, we see substantial growth runway within our immediate addressable two billion annual revenue opportunity market. We also see significant additional revenue opportunities with future indication expansion. We look forward to providing updates on our progress with these initiatives over the quarters and years ahead. Meanwhile, we intend to maintain a high degree of focus on our mission to become the standard of care for the detection and management of seizure in the acute care setting. To summarize, over the coming quarters, we intend to invest in our commercial organization to drive adoption of the Ceribell system by both new and existing accounts, continue to drive awareness of seizures in the acute care settings by maintaining a leading presence in generating clinical and economic evidence, and finally, to further scale our business to meet the growing demand for our novel EEG platform. With that, I will now turn the call over to Scott Blumberg, our CFO, to provide a review of our third-quarter results. Thank you, Jane. Good afternoon, everyone. As Jane mentioned, total revenue for the third quarter was $17.2 million, a 48% increase from $11.6 million in the same period of the prior year. The increase was primarily driven by continued commercial expansion, resulting in increased adoption of the Ceribell system across new and existing accounts. Product revenue for the third quarter of 2024 was $13.3 million, representing an increase of 52% from $8.8 million in the third quarter of 2023. Subscription revenue for the third quarter of 2024 was $3.9 million, representing an increase of 36% from $2.8 million in the third quarter of 2023. For context, we benefit from two core revenue streams. Around 75% of our total revenue is product revenue generated through a conventional razor/razor blade model, where the razor blade is our headband, a single patient use disposable. We also generate revenue from a monthly subscription-based revenue stream, which includes our EEG portal and Clarity. This high-margin recurring revenue stream accounts for approximately 25% of our total revenue. Gross margin for the third quarter of 2024 was 87% compared to 84% in the prior year period, reflecting continued pricing discipline, reductions in the cost of goods sold of our headbands, and better leverage of our manufacturing overhead. As we look ahead, we plan to continue to drive gross margin expansion and operating efficiencies where possible. Total operating expenses for the third quarter of 2024 were $24.9 million, an increase of 48% compared to $16.9 million in the third quarter of 2023. The increase in operating expenses was primarily attributable to investment in the Ceribell commercial organization expansion, increased headcount to support growth of the business, and expenses primarily attributable to legal, accounting, and professional service fees, including expenses related to our transition to becoming a public company. Net loss was $10.4 million for the third quarter of 2024, or a loss of $1.85 per share, compared to a loss of $7.1 million or a loss of $1.32 per share in the third quarter of 2023. Note that the weighted average share count of 5.6 million used to determine loss per share for Q3 2024 does not reflect the closing of our IPO on October 15. New shares issued in connection with the closing of the IPO include 12.2 million shares issued in the offering and 17.8 million shares issued upon conversion of convertible preferred stock into common. These shares will be incorporated into the weighted average share count for the fourth quarter of 2024. Our cash and cash equivalents as of September 30, 2024, were $14.1 million. This does not include net proceeds of approximately $188 million from our IPO. As Jane mentioned, we believe the net proceeds we raised from our IPO put us in a strong position to continue investing in growth while enabling us to comfortably achieve cash flow break-even with cash on hand. Turning now to our outlook for the remainder of 2024, we expect full year 2024 total revenue to be in the range of $64.2-$64.7 million, representing annual growth of 42%-43% over the full year of 2023. This implies sequential revenue growth in Q4 over our particularly strong Q3, in which we benefited from typical seasonal dynamics and less typical timing of a handful of large orders. While we do not provide guidance on the account base, it's worth noting that we have made a strategic decision to continue the practice that we began in 2023, in which we defer launching new accounts in the second half of December. This approach is grounded in our historical experience, but it's better to avoid launching during the holidays, as we believe uninterrupted attention on high-quality launch is necessary to maximize usage during the first few weeks following launch, which we believe is a positive indicator for long-term utilization rates. Overall, we remain encouraged by our third-quarter performance, our strong margin profile, and the underlying unmet need and demand for our platform. We also see our account backlog is stronger than ever. Following our IPO, we are well-positioned financially and believe we have a clear path to delivering sustained future growth. With that, I'll turn the call back to Jane. Thank you, Scott, and thank you all for your time today. We appreciate your support and continued interest in Ceribell as we work towards achieving our mission to become the standard of care for the detection and management of seizures in the acute care setting. We look forward to providing you with updates on our progress in the quarters to come. With that, I will now turn the call over to the operator for any Q&A. At this time, I would like to remind everyone, in order to ask a question, press star one on your phone keypad. We will pause for just a moment to compile the Q&A roster. And your first question comes from the line of Travis Steed with Bank of America. Your line is open. Hi, this is Stephanie Piazzola on for Travis. Thanks for taking the question and congrats on the third quarter here. I wanted to ask a question on utilization, curious if there's any more detail that you can share on utilization trends in the quarter and maybe what are some of the underlying assumptions for Q4 and maybe early thoughts about next year, just high-level how utilization can trend relative to the steady growth that you've been seeing there. Hey, Stephanie. Scott, thanks for the question. We, as you know, driving utilization is a core part of our strategy, and we've been effective in that and continue to be effective in that. We do have a small degree of seasonality as we think about Q3 and Q4 relative to Q2, but we saw the growth in Q3 was consistent with what we expected, and we expect to keep driving that going forward. I also will point out that we break out our product revenue as part of our income statement, so you should be able to track along to look at the quality of revenue per account. Thanks. And then maybe just one follow-up question, maybe more high-level, just wanted to get the latest thoughts on how you'll use the IPO proceeds and areas of investment for future growth and if you're thinking about center adds or sales rep hires any differently. Thanks for taking the questions. Sure. Yeah, of course, we ended up raising quite a bit more than we initially set out to, so we're evaluating various opportunities to drive further growth. Fortunately, our IPO came right as we were starting our 2025 operating plan process, so we're evaluating in real time. Our core principle, of course, is going to be that the cash has to achieve break-even, but we are planning to look at various initiatives both on sales and R&D in order to drive future growth. Your next question comes from the line of Robbie Marcus with J.P. Morgan. Your line is open. Hi, this is Lily on for Robbie. Thanks for taking the question and congrats on the first quarter as a public company. As we think about fourth quarter in 2025, what do you see as the main levers that you're pulling to drive growth from here? Is the priority to continue to drive penetration in existing accounts? Are you focusing on rolling out into new ones? Is it expanding the sales force? So what are you prioritizing, and where do you see the most potential for upside here? Sure. Yeah, you nailed it. The two biggest levers are driving more accounts and driving adoption within the accounts. Those have been and will continue to be our two levers. As you know, we've been focused on expanding our sales team on the territory manager side who drive account acquisition. We're working to build that up. That won't impact Q4, so that's more of a longer-term lever. The way I would think about it is on the short-term, utilization is for Q4, utilization is the more effective way to drive growth, and over the long-term, net new ads or adding new accounts is the more effective way to drive growth. Got it. That's helpful. And then just as a follow-up, I was hoping to get a bit more color on the VA approval. I think I heard you say 200 hospitals total. So should we be expecting you to launch in all of those accounts, and when do you expect those accounts to become active and start contributing to the model? Thanks so much. Yeah. The VA 200 account, we do not see this ATO impact the near-term revenue. This is more approval or license to hunt, if we may frame that way. This opens the doors for us to potentially enter the 200 accounts. Our initial TAM, we communicated 5,800 hospitals in the U.S. That does not include this 200. So now we are essentially expanding our TAM to 6,000 facilities in the U.S. We'll treat the VA accounts very similar or equivalent to other hospitals we are pursuing. So we will see the potential upside moving forward, but not impacting the near-term revenue forecast. Great. Thanks so much. Your next question comes from the line of Margaret Kaczor Andrew with William Blair. Your line is open. Hey, everyone. This is Macauley on for Margaret tonight. Thanks for taking our question and want to echo the congrats on the solid first quarter as a public company. Scott, I know you touched on some of the seasonality, and it was great to see the 25 new account adds this quarter. But if we look at new account adds in the fourth quarter, the last three years, I think you've averaged a high single-digit sequential decrease, which would imply around mid-teens, call it 16, 17 new adds next quarter. So wondering if that's the right way to think about it for this year and maybe heading into next year, what we should imply for account adds on a sequential basis. Yeah, Mcauley. So the main factor there, at least for last year and this year, I don't know that we did it to the same extent two years ago, is our strategic decision not to launch accounts after mid-December. What we found is that during that period when a lot of the doctors and nurses are on holiday, you either don't get the mind share or you don't have them there consistently enough to build the habits you need to have a high-quality launch. So we've made the decision to effectively, except for in special circumstances, shut down launches in mid-December. Those effectively get pushed into Q1. So I guess that's seasonality, but it's seasonality driven by our strategic decision rather than the market in that case. That's helpful. And then maybe just one on the expansion opportunities that you mentioned within stroke and delirium. Wondering how enrollment is tracking in the 200-patient delirium trial? It looks like it has an estimated completion date by the end of this year. So wondering if you could provide any updates there or maybe an expected release for timing, call it first half 2025? Yeah. We continue to enroll the patients at the historical rate as we have been, especially on the delirium front. On the stroke front, we are exploring to potentially recruit even more sites so we can enroll patients even faster, and the nature of both of these studies is more for data collection to train the algorithm, so there is no formal readout at the end of the enrollment of both studies. Sounds good. Thanks again for taking the questions. Thank you. Your next question comes from the line of Josh Jennings with TD Cowen. Your line is open. Hi, good evening. Thanks for taking the questions and congratulations on the strong results. I wanted to just focus on the cost-effectiveness of the Ceribell platform. I mean, it's pretty impressive. You just had a study published showed a four-plus day length of stay decrease, and that's usually the low-hanging fruit for technologies. But you have revenue-generating potential for adopting customers. I mean, maybe you could just help us think through that. I think decreasing transfers, upcoding to a major comorbidity or complication, maybe anything else you can list and how impactful it is as you're marketing the platform to new adopters. Yeah. Josh, you summarized it well. For us to provide not just the clinical impact, but also the economic impact to the hospitals is a major driver and is incredibly important for our customers. For all the drivers you have listed, different drivers resonate with different hospitals. And so far, for instance, more remote or smaller hospitals that transfer patients out more frequently, the reduction of transfer would resonate with them more. And some facilities are very much putting the capacity management of ICU as their top priority, so the ICU reduction would resonate more. And as we move forward, we will continue building even more both clinical as well as economic evidence to support our continuous expansion and our adoption of the technology. Thanks. Just to follow up on that, I mean, do you see the cost-effectiveness come in at a higher level with customers that adopt Clarity Pro? And maybe you can help us think about the attachment rate this quarter for new adopters. I think it's extremely high, about 100%. But also just the early adopters that haven't adopted Clarity Pro and any traction there, and are you seeing conversions from that historic base? Thanks for taking the questions. So just to make sure I understand the question, what's the percentage of customers who have converted from base to Clarity and also how much hospitals are adopting Clarity Pro? All our new accounts, we use 100% using our AI algorithm, Clarity or Clarity Pro. And with Clarity Pro, we are still in the process of driving adoption because there are additional associated fees that customers need to pay for Clarity Pro. And we are only one year in the NTAP, so we are driving both fronts for Clarity and Clarity Pro moving forward. Excellent. And do you see improved cost-effectiveness profile for customers that have Clarity Pro, or is it pretty similar for Clarity and Clarity Pro for the different algorithms? The clinical benefit is even stronger for customers who have Clarity Pro. And in terms of the behavior, user behavior or profile, so far, we have not seen a major difference that separates the two. Fantastic. Thanks, Jane. Sure. Your next question comes from the line of Bill Plovanic with Canaccord Genuity. Your line is open. Great. Thanks. Good evening, and thanks for taking my questions. Really, I just wanted to circle back on the VA ATO. I think, Jane, you mentioned that the 200 VA accounts were incremental. So would I just want to assume that you weren't selling into the VA today, and this gives you the hunting license in the future? Or do you already have some VA accounts, and this allows you to transition those to Clarity accounts? Thank you, Bill, for the question. We have some very small number of accounts that are existing VA accounts. But because they cannot have any cloud product and service, so the current VA customers only have the bedside recorder to record EEG. And they don't have access to Clarity. They also don't have access to our cloud-based EEG reading portal. So it's very difficult for neurologists to review. So as you could imagine, because it's a very small portion of our product solution, the usage has been rather limited. Because both the usage as well as the number of accounts are rather limited, it's probably the best way to think about the 200 hospital VA as all new account acquisition than converting existing customers to Clarity. Does this ATO allow you with the VA, is it separate contracting to be able to bring in the Clarity, which is kind of why you're cautious about the time to ramp? Because you have to turn around with contracting and get the addition of the Clarity monthly fee. That's right. So the ATO is more approval of all the VA systems to use Clarity and our portal, which they were not able to do before. It's separated from the commercial contract. From the commercial contract perspective, it's going to be like many other hospital systems. It's a combination of bottom-up sale that we go to individual facilities, getting both the physician as well as administrator support, and a combination of top-down working with some of the headquarters decision-makers as well. So it's similar to other hospital systems we're working with. Okay. And then for Scott, just the proceeds raised in the IPO were double what you expected. I mean, it gives you guys a huge cash cushion. And I think somebody asked earlier in regards to the incremental cash, plans on either investing in going after OUS sooner or new indications sooner. And I think you said that's part of the process as you're planning for 2025, given all the new information. When could we expect messaging and more clarity around kind of your future plans, given the incremental cash you raised? And thanks for taking my questions. Thanks, Ceribell. I think we probably will be able to talk about some of it on our next call, right? Because at that point, we'll have our operating plan built and approved by the board. There's other things, of course, like our clinical data where we'll give news as it comes out, which, as we've indicated in S-1, is two to four years for delirium and stroke. But as far as the use of proceeds question, I think we'll have more granularity on that in a few months here. Thank you. I will now turn the call back over to Jane for closing remarks. Thank you and really want to thank everyone's time and your support to Ceribell and we are very excited for our future and thank you for our first earnings call. Have a great afternoon or evening. Ladies and gentlemen, that concludes today's call. Thank you all for joining. You may now disconnect.